SANGAMO THERAPEUTICS, INC
8-K March 30, 2026
Key Highlights
- Strategic pivot to a neurology-focused biotech model
- Advancement of ST-920 for Fabry disease into late-stage testing
- Proprietary 'zinc finger' gene-regulation technology platform
Read Analysis
🤖 AI Generated